Showing 1,901 - 1,920 results of 144,589 for search '(( i we decrease ) OR ( 5 ((point decrease) OR (((nn decrease) OR (a decrease)))) ))', query time: 2.32s Refine Results
  1. 1901
  2. 1902
  3. 1903
  4. 1904
  5. 1905
  6. 1906
  7. 1907
  8. 1908
  9. 1909
  10. 1910
  11. 1911
  12. 1912
  13. 1913
  14. 1914
  15. 1915
  16. 1916

    <b>Dihydroxyacetone decreases the dATP pool, inducing replication stress and genomic instability in BEAS-2B cells</b> by Saddam Hussain (22282372)

    Published 2025
    “…Using a DNA fiber assay we observed decreased replication fork progression, which coincided with increased micronuclei formation. …”
  17. 1917

    Cholesterol Corrects Altered Conformation of MHC-II Protein in <i>Leishmania donovani</i> Infected Macrophages: Implication in Therapy by Koushik Roy (193484)

    Published 2016
    “…<div><p>Background</p><p>Previously we reported that Kala-azar patients show progressive decrease in serum cholesterol as a function of splenic parasite burden. …”
  18. 1918

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  19. 1919

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 1920